The outcome of regulatory inspections is critical to an organization’s success. The FDA performs inspections to check that companies are maintaining compliance with applicable regulations and quality standards. Though you do your best to avoid it, receiving a 483 or Warning Letter is inevitable. It’s important to take the observations very seriously because you only have 15 days to submit the subsequent responses.
But ensuring that you are aware and understand what the regulatory agency is expecting in the response can be a challenge. What should you include? What are the risks of not submitting an appropriate response?
This 90-minute course will discuss the importance of developing and submitting a robust, timely response to FDA 483 observations or warning letters; as well as, educate the audience on the essential elements of a thorough response. Additionally, this course will review the proper structure of the response to ensure the regulatory agency’s expectations are met and the submission process.
At the completion of this session, you will be able to:
This course will be valuable to anyone engaged in the development, manufacturing, sale, or distribution of FDA-regulated healthcare products. Additionally, this course will provide a good primer for those involved in writing observation responses. This includes personnel in:
At the completion of this session, you will be able to:
This course will be valuable to anyone engaged in the development, manufacturing, sale, or distribution of FDA-regulated healthcare products. Additionally, this course will provide a good primer for those involved in writing observation responses. This includes personnel in:
Kelly Thomas
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
Building a High-Performance Team in 90 Days
Introduction to Microsoft Power BI Dashboards
Bootcamp for New Managers and Supervisors: Develop These Es…
Dealing with Difficult People: Managing Strong Personalitie…
The Perfect Storm Coming to Healthcare: Value Based Care Me…
Excel - Lists and Tables - A Beginner's Guide to Managing L…
Reinvent Your HR Department with ChatGPT
DOL Reverses Course on Independent Contractor Rule for 2026…
Using Claude in Excel for Productivity, Automation & Data A…
Stop Letting That Difficult Person Ruin Your Day: Effective…
FDA Technology Modernization Action Plan (TMAP) and Impact …
GROUPBY and PIVOTBY functions. Pivot table killers?
Discover how Emotional Intelligence turns AI from a technic…
Sunshine Act Reporting - Clarification for Clinical Research
Faster, Better Talent Acquisition: Leveraging AI & ChatGPT …
Cleanroom, Microbiology and Sterility Assurance Practices f…
FDA Recommendations for Artificial Intelligence/Machine Lea…
Interactive dashboards & analytics in Excel
Data Integrity and Privacy: Compliance with 21 CFR Part 11,…
Language is Code - Intro to AI - Generative AI - ChatGPT an…
FDA Audit Best Practices - Do's and Don'ts
Medical Device Hazard analysis following ISO 14971
